Mylan Launches Generic Myfortic

Mylan announced the launch of Mycophenolic Acid  Delayed-Release Tablets, the generic version of NovartisMyfortic.

RELATED: Immune Disorders Resource Center

Mycophenolic Acid is an immunosuppressant indicated for the prophylaxis of organ rejection in adults receiving kidney transplant, and for the prophylaxis of organ rejection in pediatric patients >5 years who are at least 6 months post kidney transplant.

Mycophenolic Acid exhibits a cytostatic effect on T- and B-lymphocytes by inhibiting inosine monophosphate dehydrogenase (IMPDH). Blocking this pathway inhibits de novo guanosine nucleotide synthesis, therefore suppressing T- and B-lymphocyte proliferation.

Mylan’s Mycophenolic Acid Delayed-Release Tablets are available in 180mg and 360mg dosage strengths.

For more information call (800) RX-MYLAN or visit